Pennsylvania Record

Wednesday, February 19, 2020

After $8 billion verdict, J&J wins two Risperdal cases in Philadelphia

State Court

By Nicholas Malfitano | Dec 17, 2019

Risperdal
Risperdal

PHILADELPHIA – In stark contrast to the $8 billion punitive damages verdict reached this past fall, two Risperdal cases were dismissed through successful motions for summary judgment from Johnson & Johnson in Philadelphia courtrooms.

Philadelphia County Court of Common Pleas Judge Arnold L. New dismissed Davis v. Janssen Pharmaceuticals Et.Al on Dec. 3 and Dennis v. Janssen Pharmaceuticals Et.Al on Dec. 6, following the filing of summary judgment motions by the makers of Risperdal last spring.

In Dennis, plaintiff Fredrick Dennis of Chicago filed suit, having purchased and taken Risperdal in 2008. Dennis claimed personal injury in the form of gynecomastia, or the development of female breast tissue, and economic loss in his complaint, along with 12 counts against the Janssen defendants.

He also filed charges including fraud, conspiracy and punitive damages against Elsevier and Excerpta Medica, Inc.

In Davis, plaintiff Dartric Davis of Houston also filed suit, having purchased and taken Risperdal from the summer to the winter of 2007, and once in February 2009. Davis also claimed personal injury in the form of gynecomastia and economic loss in his complaint, in addition to 12 counts against the Janssen defendants.

Both plaintiffs demanded a trial by jury.

While the Dennis action was dismissed on the basis of summary judgment, the Davis case was as well, but also with the proviso that particular case violated the governing statute of limitations – even after a Supreme Court of Pennsylvania ruling last month opened the door to reinstating thousands of Risperdal cases on those very same grounds.

Counsel for the plaintiffs was not available for comment to the Pennsylvania Record.

Johnson & Johnson released a statement on the successful motions.

“The company will continue to vigorously defend itself in ongoing Risperdal litigation. Risperdal is an important U.S. FDA-approved prescription medicine that, when used as part of a comprehensive treatment plan, continues to help millions of patients with mental illnesses and neurodevelopmental conditions,” the company said.

According to current statistics from the Philadelphia County Court of Common Pleas and its Complex Litigation Center, nearly 7,100 cases have been filed in Risperdal litigation in that particular court system. Many of them emanate from out-of-state plaintiffs, with that contingent covering 86 percent of pharmaceutical cases in Philadelphia courtrooms.

Philadelphia County Court of Common Pleas cases 170205461 & 170205885

From the Pennsylvania Record: Reach Courts Reporter Nicholas Malfitano at nick.malfitano@therecordinc.com

Want to get notified whenever we write about any of these organizations ?

Sign-up Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Kline & Specter PCJohnson & Johnson

More News